Blue­bird hits the brakes on Lenti­Glo­bin stud­ies, Zyn­te­glo mar­ket­ing af­ter AML, myelodys­plas­tic syn­drome cas­es spur fresh safe­ty con­cerns

Blue­bird bio $BLUE has run in­to a fresh set of trou­bles for its gene ther­a­py Lenti­Glo­bin.

The biotech, which has seen its gene ther­a­py work mired at the FDA due to CMC is­sues, re­vealed Tues­day morn­ing it had sus­pend­ed work on its ear­ly-stage study as well as the Phase III sick­le cell tri­al for Lenti­Glo­bin in or­der to in­ves­ti­gate two more se­ri­ous side ef­fects among pa­tients in the pro­gram.

In ad­di­tion, blue­bird CEO Nick Leschly hit the brakes on mar­ket­ing Zyn­te­glo (betibeglo­gene au­totem­cel; beti-cel) in Eu­rope, where it’s ap­proved for be­ta tha­lassemia, be­cause it us­es the same BB305 lentivi­ral vec­tor used in the gene ther­a­py for sick­le cell dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER